← Eichor
Condition: Cellular Pathology Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cellular Pathology

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outco
Phase N/A · 2 location(s) · Artcline GmbH · NCT06143137Comparison Between Epidural Analgesia and Intrathecal Opioid Analgesia for Pain Management in Open Nephrectomy
Phase 1 · 1 location(s) · University Hospital of Split · NCT06595329Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Spectroscopic Analysis of Tongue Tumor Samples.
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT05104619A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considerin
NA · 1 location(s) · Columbia University · NCT05963971A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Phase 2 · 4 location(s) · Dana-Farber Cancer Institute · NCT05168930Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
NA · 1 location(s) · University of Surrey · NCT06379282Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DF
NA · 1 location(s) · C5 Biomedical · NCT06674980MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06262386CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT07001631A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib
Phase 3 · 91 location(s) · BeOne Medicines · NCT07277231Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454REgulatory T Cell Therapy to Achieve Immunosuppression REduction
Phase 2 · 7 location(s) · Singulera Therapeutics Inc. · NCT06552169Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03128879Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05366179
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.